Objectives: To compare the effectiveness in the treatment of erectile dysfunction when using PDE-5 inhibitors (PDE5i), alprostadil (PG-E1) and testosterone (TES) in SummaryNo conflict of interest declared.
The pathologies which most needed blood components' transfusions in the Urology Department were (in order of frequency): bladder cancer, kidney cancer, prostate cancer, prostate adenoma. ASA100mg did not influence the transfusion's requirements in VTUR due to BTCC. Tumour stage and higher grade have a greater influence in transfusion's requirements than concomitant AP/AC treatment. The heterogeneity of AP/AC protocols does not allow to establish the benefit of stopping those drugs before surgery in terms of avoiding blood transfusions when performing a VTUR.
Objective: To study whether there are factors related to secondary diagnoses (SDg) present in patients with prostate cancer that influence the development of urinary incontinence after radical prostatectomy (RP). Materials and methods: A retrospective multicenter observational study was performed reviewing the medical records of 430 men who underwent RP due to organ-confined prostate cancer in 9 different hospitals. Two study groups were distinguished: Group A (GA): Patients without urinary incontinence after RP; Group B (GB): patients with any degree of post-surgical urinary incontinence. Results: Average age at surgery was 63.42 years (range 45-73). 258 patients were continent after surgery and 172 patients complaint of any degree of incontinence after RP. A higher percentage of healthy patients was found in group A (continent after surgery) than in group B (p = 0.001). The most common SDg prior to surgery were hypertension, lower urinary tract symptoms, dyslipidemia, diabetes mellitus and erectile dysfunction, but none did show a greater trend towards post-surgical incontinence. Conclusions: A better health status prior to surgery is associated to a lower incidence of new-onset urinary incontinence after radical prostatectomy. However, no correlation was found between the most common medical disorders and the development of post-surgical urinary incontinence.KEY WORDS: Radical prostatectomy; Second diagnoses; Urinary incontinence. dence of tumour cells in the prostate (1), a 9.5% will have risk of being diagnosed with prostate cancer throughout their life, and 3% of them will have the probability of dying due to this disease (2, 3). Histological signs of prostate cancer have been found in 42% of patients who died due to other causes (4, 5). Most prostate cancers are organ-confined at diagnosis (6). When the patient's life expectancy is 10 years or greater and his health status is compatible with general anaesthesia, radical prostatectomy achieves the best results in oncological terms (7). Radical prostatectomy is a complex major surgery, which requires dissection and removal of all the prostate gland and disruption and modification of a large part of the anatomical structures that makes up the male sphincteric complex. The different muscles, ligaments and neurovascular elements of the sphincteric complex converge in the prostate apex, in an anatomical funnel, whose upper limit is the prostate gland. The development of urinary incontinence (UI) is one of its most feared complications and is attributed to the technical characteristics of the surgery. The factors that may be associated to an increased risk of developing UI after surgery have been studied, i.e, ageing and deliberate wide resection of the cavernous nerves. The aim of this study was to evaluate whether there are factors related to secondary diagnoses (SDg) present in patients that influence the development of UI after radical prostatectomy (RP).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.